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ABSTRACT: Synthesizing iron oxide nanoparticles for
positive contrast in magnetic resonance imaging is the most
promising approach to bring this nanomaterial back to the
clinical field. The success of this approach depends on several
aspects: the longitudinal relaxivity values, the complexity of
the synthetic protocol, and the reproducibility of the synthesis.
Here, we show our latest results on this goal. We have studied
the effect of Cu doping on the physicochemical, magnetic, and
relaxometric properties of iron oxide nanoparticles designed to
provide positive contrast in magnetic resonance imaging. We
have used a one-step, 10 min synthesis to produce
nanoparticles with excellent colloidal stability. We have
synthesized three different Cu-doped iron oxide nanoparticles showing modest to very large longitudinal relaxivity values.
Finally, we have demonstrated the in vivo use of these kinds of nanoparticles both in angiography and targeted molecular
imaging.
1. INTRODUCTION
The reduction of transverse relaxation time (T2) and the
longitudinal relaxation time (T1) of water protons are the two
main types of contrasts generated in magnetic resonance
imaging (MRI). The first approach produces a darkening of
the areas in the image where the probe has accumulated,
whereas the second renders a brightening of the image. For
technical and physiological reasons, a T1-based contrast is
preferred by radiologists and physicians for diagnostic
purposes. From the imaging point of view, this is a key aspect,
being one of the main reasons why “traditional” iron oxide
nanoparticles (IONPs), for T2-weighted imaging, have not
been established as an alternative in the clinical practice. The
quest for new iron oxide nanoparticle-based probes for
magnetic resonance imaging (MRI) has traditionally focused
on the obtainment of transverse relaxivity values (r2) as large as
possible.1 Over the last years, the attention has moved to the
development of IONPs as “positive” contrast agents, showing
large longitudinal relaxivity values (r1). The rationale behind
this approach is trying to get the best of both worlds:
commonly used contrast agents in MRI, Gd chelates, and
nanoparticles. In other words, to have a good, easy to spot,
signal in MRI without a noticeable toxicity, multifunctionaliza-
tion, and the possibility of easily tuning the pharmacokinetics
of the probe. Two aspects are crucial for a good T1-based
contrast agent: a large r1 value and a small r2/r1 ratio. The most
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common approach to obtain IONPs as T1 contrast agents is by
reducing the core size. Due to the large surface effects, IONPs
become more paramagnetic than superparamagnetic and the
inner-sphere relaxation mechanism of water protons domi-
nates.2 Alternatively, it is possible to modify the chemistry of
the coating molecules on the nanoparticles to obtain T1-
weighted contrast out of IONPs in vivo.3 A third option is the
core doping of the IONPs with different metals: a few
examples describe an increase of the r2 values (using Co, Ni,
Zn, or combinations of them)4−7 and fewer for positive
contrast (mainly with Mn or Gd as the doping metal).8−10 The
use of Cu as a dopant, alone or in combination with other
metals, in iron oxide nanoparticles, is limited, compared, for
example, to its use as a dopant in ZnO nanoparticles. Cu
doping effect has been studied in catalysis,11 sensor perform-
ance,12,13 and in the magnetic properties of the nanomateri-
al.14−16 The use of Cu as a dopant for molecular imaging is
limited, with one example, in combination with Co, using
nanorods for MRI17 and one example where the 64Cu
radioisotope is used for positron emission tomography.18
Interestingly, in both cases, the relaxometric properties of the
nanomaterials make them suitable exclusively for T2-weighted
MRI (dark contrast). Furthermore, there are no studies on the
use of Cu doping as a way to obtain nanoparticles for positive
contrast MRI.
The use of microwave-driven synthesis (MWS) for the
production of nanomaterials is a versatile and highly
reproducible approach. We have demonstrated how this
methodology can produce, in extremely short times,
homogeneous nanoparticles with excellent properties for
molecular imaging.3,19 However, in the production of nano-
particles for T1-weighted MRI, the use of MWS is far from
common. Most of the syntheses used for the production of T1
nanoparticles are characterized by time-consuming proto-
cols,8−10,20,21 multistep approaches,9,10,22−26 or the use of
organic solvents.22−26
Here, we have studied the effect of Cu doping of iron oxide
nanoparticles on their relaxometric properties. In a 10 min,
Figure 1. (a) Synthetic scheme for Cu1.7-NP, Cu4-NP, and Cu28-NP; (b) hydrodynamic size distribution, measured by dynamic light scattering
(DLS); (c) Z-average size (mean with standard deviation, N = 5, P = 0.0001) and (d) ζ-potential for iron oxide nanoparticles (IONPs), Cu1.7-NP,
Cu4-NP, and Cu28-NP; and (e) Fourier transform infrared (FTIR) spectra and (f) thermogravimetric curves for Cu1.7-NP, Cu4-NP, and Cu28-
NP.
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one-pot synthesis, we have produced Cu core-doped IONP
(Cu-NP) with the largest longitudinal relaxivity value
described so far, at clinically relevant magnetic fields. We
have fully characterized the new nanomaterial and demon-
strated its suitability for in vivo use in angiography and
targeted molecular imaging for the enhanced diagnosis of
tumors in animal models.
2. RESULTS AND DISCUSSION
2.1. One-Pot Microwave-Driven Synthesis of Cu-
Doped Hydrophilic Iron Oxide Nanoparticles. Microwave
synthesis of nanoparticles is a reliable, reproducible, and
extremely fast way for the production of small iron oxide
nanoparticles (IONPs). We recently used this approach to
tune the relaxivity values of extremely small iron oxide
nanoparticles, from T2 agents to T1 agents.
3 Here, we have
synthesized three different iron oxide nanoparticles with an
increasing amount of Cu core doping (Figure 1a). In a typical
synthesis, we mixed FeCl3, sodium citrate, and hydrazine with
different amounts of CuCl2 (15, 45, and 74 μmol); after 10
min of heating at 120 °C, we purified the nanoparticles by size
exclusion chromatography. After purification, we quantified the
amount of Cu in the samples by inductively coupled plasma
mass spectrometry (ICP-MS): 1.7 mol % (sample Cu1.7-NP),
4 mol % (sample Cu4-NP), and 28 mol % (sample Cu28-NP).
2.2. Physicochemical Characterization of Cu-Doped
Iron Oxide Nanoparticles. Hydrodynamic size distributions
(Figure 1b) are narrow for all of the samples. Samples IONP,
Cu4-NP, and Cu28-NP show the same size distribution,
whereas for the sample with the lowest amount of Cu (Cu1.7-
NP), the size is smaller. This is confirmed by plotting the Z-
average values for each sample (Figure 1c). Sample Cu1.7-NP
shows a much smaller size (7.7 ± 0.6 nm) than the other
nanoparticles in this study; values for IONP, Cu4-NP, and
Cu28-NP are 15.0 ± 1.0, 16.1 ± 0.7, and 16.0 ± 1.5 nm,
respectively. ζ-Potential measurements show no significant
differences between samples (Figure 1d) with homogeneous
values around −34 mV as expected for citrate-coated
nanoparticles.
FTIR spectra for the three Cu-doped samples show the
expected bands (Figure 1e); bands corresponding to citrate
coating appear at 1580, 1380, and 1090 cm−1. The band with
maxima at 1580 cm−1 is wider for Cu28-NP (from 1460 to
1720 cm−1), most likely due to the presence of the Cu−O
band that normally appears at around 1640 cm−1. A strong
band due to iron oxide is observed in all three spectra at 560
cm−1. Further analysis in the region between 800 and 400 cm−1
shows at least a band at a higher wavelength than 600 cm−1,
indicating that the sample is mainly composed of maghemite
rather than magnetite.3 Thermogravimetric analysis shows the
same curves for the three samples. We found three different
steps at around 120, 380, and 480 °C; this mass loss in a
stepwise manner is typical of citrate-coated nanoparticles.27 All
samples show a thick organic layer, about 50% of weight loss,
which ensures their colloidal stability and the availability of
carboxylic groups for bioconjugation.
Electron microscopy of these samples is often difficult; a
small core and a thick organic layer complicate acquiring
quality images. The same happens with X-ray diffraction
Figure 2. Selected STEM-HAADF images of (a) Cu1.7-NP, (b) Cu4-NP, and (c) Cu28-NP; (d) core size measured by STEM (mean with
standard deviation, N = 30, P = 0.01); (e) ratio of Cu/Fe counts in EDX; and (f) XRD profiles for the three samples.
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(XRD), which normally produces broad peaks difficult to
identify. To ameliorate this issue, we treated the samples
(Cu1.7-NP, Cu4-NP, and Cu28-NP), prior analysis, with the
enzyme citrate lyase. This enzyme catalyzes the reversible aldol
cleavage of citrate to oxaloacetate and acetate. Our hypothesis
was that by cleaving citrate the organic layer would be at least
partially reduced so scanning transmission electron microscopy
(STEM) images would be better and XRD peaks would be
more clearly defined. Figure 2 shows selected STEM-HAADF
images of the three samples (more images are shown in the
Supporting Information). Images reveal small cores for all of
them, similar to IONPs produced with this approach.3 We can
observe individual, dispersed nanoparticles, for all three
samples. The core size of the nanoparticles, measured by
STEM, also shows that Cu1.7-NP has the lowest value (3.2 ±
0.9 nm) and Cu4-NP has a similar core size (3.5 ± 0.8 nm),
whereas IONP (4.2 ± 1.0 nm) and Cu28-NP (4.4 ± 2.9 nm)
show the largest values. Interestingly, Cu28-NP, the sample
with the largest amount of Cu, shows a much higher
heterogeneity than the other nanoparticles in the core size
(Figure 2d), which is also reflected in the quality of the images
(Figure 2c). Energy dispersive X-ray (EDX) analysis of the
samples confirms the results obtained by ICP-MS, an increase
in the Cu/Fe ratio from Cu1.7-NP to Cu28-NP (Figure 2e).
The effect of the enzyme is noticeable in the quality of the
XRD spectra. A comparison with previous data on IONP,
without enzymatic treatment, clearly shows that now the peaks
are more defined and easier to identify.3 The increase in Cu
doping results in a slight displacement of the main peak (311)
toward larger angles and the decrease of the intensity in the
peaks.15 Using the Scherrer equation, we calculated the
crystallite sizes for the three nanoparticles: 2.9 nm for
Cu1.7-NP; 3.5 nm for Cu4-NP; and 3.4 nm for Cu28-NP, in
good agreement with the core sizes measured by STEM. The
field-dependent magnetization data (Figure 3a) show negli-
gible coercivity values for all of the samples, confirming their
superparamagnetic behavior. The incorporation of increasing
amounts of Cu significantly reduces the saturation magnet-
ization of the sample, even for the smallest amounts of Cu.
Saturation magnetization values are 76.6 ± 0.3 emu g−1 Fe +
Cu for Cu1.7-NP, 56.2 ± 0.3 emu g−1 Fe + Cu for Cu4-NP,
and 43.8 ± 0.4 emu g−1 Fe + Cu for Cu28-NP, showing the
dilution effect given by the increasing proportion of copper.
However, if we express the saturation magnetization on iron
basis, we obtain 78.2 ± 0.3 emu g−1 Fe for Cu1.7-NP, 58.4 ±
0.3 emu g−1 Fe for Cu4-NP, and 63.3 ± 0.4 emu g−1 Fe for
Cu28-NP. This unexpected high value for Cu28-NP supports
the core−shell structure for this sample where the excess of Cu
is mainly located on the surface of the nanoparticle core. The
temperature dependence of the out-of-phase susceptibility
shows maxima located in the range between 15 and 22 K for all
samples, together with maxima in the in-phase susceptibility at
slightly higher temperatures (data not shown) typical of the
relaxation procedure of nanoparticles (Figure 3b). The
location of the out-of-phase susceptibility is influenced by
the size distribution, composition, and aggregation (dipolar
interactions) of the particles. A mixture of factors affects our
results; the increase in the Cu amount (that would probably
reduce the saturation magnetization values and the temper-
ature location of the susceptibility maxima) is associated with
an increase in the particle size (Figures 1 and 2) that would
have the opposite effect. The negligible out-of-phase
susceptibility values at temperatures above 100 K indicate
the superparamagnetic behavior of these particles at room
temperature, in agreement with the negligible coercivity
observed in the field-dependent magnetization data.
2.3. Relaxometric Characterization of Cu-Doped
Nanoparticles. After this comprehensive physicochemical
characterization, we focused on our main goal, that is, the
study of the effect on the relaxometric values of Cu core
doping. Figure 4a−c shows the plot of averaged points for r2
and r1 for the three nanoparticles. In all cases, we observe a
good linear fitting of the measured points and a good
reproducibility. A comparison of the relaxometric values for
the three Cu-doped nanoparticles (Figure 4d−f) shows some
remarkable results. The longitudinal relaxivity (r1, Figure 4d)
shows that sample Cu4-NP has a large r1 value (15.7 ± 0.6
mM−1 s−1), significantly larger than that for iron oxide
nanoparticles (11.9 ± 0.3 mM−1 s−1). The r2 value is also
larger for Cu4-NP; however, the r2/r1 ratio is pretty low (2.1),
in summary, excellent conditions for T1-weighted magnetic
resonance imaging. Sample Cu1.7-NP also shows an improved
performance in the longitudinal relaxivity (13.6 ± 0.3 mM−1
s−1), compared to that of IONP. The transversal relaxivity
value is similar to that for Cu4-NP, and the r2/r1 ratio is
slightly larger. These properties make Cu1.7-NP also an
optimal contrast agent for T1-weighted imaging, second only to
the excellent results for Cu4-NP. Finally, the sample with the
largest amount of Cu shows poor performance as an MRI
contrast agent. The r1 value (8.5 ± 1.3 mM
−1 s−1) is much
smaller than the value for IONP, and the r2/r1 ratio is the
largest for the series (2.4). The relaxometric study shows that,
under tested conditions, a 4 mol % doping provides the best
properties for an improved T1 contrast. A large doping
percentage, as in Cu28-NP, renders nanoparticles with worse
T1 contrast than that of nanoparticles without doping.
Figure 3. (a) Magnetization curves at 298 K and (b) temperature
dependence of AC magnetic susceptibility for IONP, Cu1.7-NP, Cu4-
NP, and Cu28-NP.
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Magnetic measurements suggest a core−shell structure for
Cu28-NP, with most of the Cu atoms on the surface; this
explains the small r1 value since Cu atoms on the surface would
reduce the contribution of the inner-sphere relaxation
mechanism. In Cu1.7-NP, we see an improvement in the T1
signal but lower than for the 4% doping conditions. It seems
that around this doping percentage we obtained the
appropriate reduction of the magnetization, keeping enough
Fe atoms on the surface. The 1.7% doping is too small to see
the full effect, whereas the 28% doping seems too large to keep
the desirable relaxometric properties of the iron oxides
prepared this way. Surface coating thickness is a key parameter
to improve r1 values, as we have demonstrated before.
3 Cu4-
NP coating is thinner than IONP coating; this feature also
contributes to increase the longitudinal relaxivity value (Figure
S4). The r1 values shown by Cu4-NP are similar to or larger
than those of many clinical Gd- and Mn-based compounds,
and Cu4-NP has a low r2/r1 ratio.
30 We can compare these
results with those of nanoparticles for T1-weighted MRI
published in recent years (Table 1). This table includes not
only iron oxide nanoparticles but also Gd- and Mn-based
compounds. The performance of an MRI contrast agent for T1-
weighted imaging is based on the r1 value and the r2/r1 ratio.
The larger the r1 value and the smaller the r2/r1 ratio, the
better. Considering this, Cu4-NPs are one of the best suited
nanoparticles for positive contrast MRI thus far reported.
These nanoparticles have one of the largest r1 values and one
of the smallest r2/r1 ratios. It is noteworthy how the
combination of citric acid and iron oxide can produce
nanoparticles with large r1 values but poor r2/r1 ratios.
24
One of the few examples of iron oxide nanoparticles doped
with Cu shows good relaxometric properties but for T2-
weighted imaging, confirming the nanoparticles must be
considered as a whole to optimize the MRI performance.
SPIONS21 and MION28 show remarkable properties as T1
agents, with large r1 values. However, this is usually achieved
Figure 4. Plots of relaxation rates, T1 and T2, against iron and copper concentration for (a) Cu1.7-NP, (b) Cu4-NP, and (c) Cu28-NP. Plots of (d)
r1 (mean with standard deviation, N = 5, P = 0.001), (e) r2 (mean with standard deviation, N = 5, P = 0.0001), and (f) r2/r1 for IONP, Cu1.7-NP,
Cu4-NP, and Cu28-NP.
Table 1. Relaxometric Properties of Nanoparticles with Large r1 Values (> 4 mM
−1 s−1)
name composition r1 (mM
−1 s−1)/field (T) r2 (mM
−1 s−1)/field (T) r2/r1
core size
(nm)
HD
(nm) references
MnIO diethylene glycol−BSA−Mn−iron oxide 8.24/0.55 17.95/0.55 2.2 5.0 5.9 9
DIO−Cu dextran−iron oxide−Cu 17.1/1.4 135.8/1.4 7.9 5.3 45.7 18
MnFe2O4 polymers−Mn−iron oxide 6.61/4.7 35.92/4.7 5.4 2.2 5.6 8
MION dextran−iron oxide 16.5/0.47 34.8/0.47 2.1 4.6 20 28
PO−PEG−IO phosphine oxide−PEG−iron oxide 4.78/3 17.5/3 3.7 2.2 15 25
Fe2O3−citrate citric acid−iron oxide 14.5/1.4 66.9/1.4 4.6 4.8 18 24
PEG1100−IO PEG1100−iron oxide 13/1.4 42/1.4 3.2 2.8 10 22
Fe3O4@SiO2(Gd−DTPA) silica−iron oxide−Gd 4.2/3 17.4/3 4.1 27 29
UMIONS polymers−iron oxide 8.3/4.7 35.1/4.7 4.2 3.3 7.5 20
SPIONS carboxyPEG−iron oxide 19.7/1.5 39.5/1.5 2.0 5.4 10 21
IONP citric acid−iron oxide 11.9/1.5 22.9/1.5 1.9 4.2 15.0 3
Cu4-NP citric acid−Cu-doped iron oxide 15.7/1.5 32.8/1.5 2.1 3.5 16.1 this work
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after a lengthy and time-consuming synthesis and purification.
This can compromise the reproducibility and is certainly not
the best scenario for clinical translation. These nanoparticles
also show a relatively thin organic layer that could complicate
their stability under physiological conditions. In the case of
Cu4-NP, we achieved one of the best relaxometric properties,
in one single step and with a thick organic coating, ensuring
their colloidal stability under most relevant physiological
conditions.
2.4. Magnetic Resonance Angiography with Cu-
Doped Nanoparticles. A good contrast agent for in vivo
magnetic resonance imaging must have excellent relaxometric
properties. This alone is insufficient, and appropriate in vivo
behavior, factors like pharmacokinetics and colloidal stability
under physiological conditions, must be checked; for this, the
best test is an in vivo image. We carried out magnetic
resonance angiography with Cu1.7-NP, Cu4-NP, and Cu28-
NP (Figure 5) to check the potential of their T1 signals. We
acquired images before nanoparticle injection (baseline) and
15, 30, and 45 min post injection. The differences between the
nanoparticle samples are clear. Angiography with Cu4-NP
provides high-quality images with fine details of the vasculature
up to 30 min post injection.
The use of Cu1.7-NP provides positive contrast after 15
min, although the signal is not that clear as that for Cu4-NP;
then, the signal becomes weaker after 30 min of circulation.
We attribute this difference to the r1 and r2/r1 values for Cu4-
NP since the circulating time for Cu1.7-NP is similar to that
for Cu4-NP (Figure S5), discarding a rapid renal elimination as
the cause for this difference. Angiographic images with Cu28-
NP show the poorest results due to the smaller r1 value, half of
that for Cu4-NP, and a shorter circulation time.
2.5. Tumor Detection by Magnetic Resonance
Imaging: Comparison between IONP and Cu4-NP. We
have shown that Cu4-NPs provide an excellent signal in
angiographic MRI with adequate in vivo behavior. We wanted
to verify the use of this new contrast agent using actively
targeted molecular imaging and compare it with the undoped
Figure 5. MRI (T1-weighted imaging) body angiography in healthy mice, before and after the intravenous injection, 0.04 mmol Fe kg
−1, of (a)
Cu1.7-NP, (b) Cu4-NP, and (c) Cu28-NP.
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nanoparticles, IONPs. We designed a classical experiment, that
is, targeting vascular angiogenesis toward integrin αvβ3 in
tumor models using RGD peptide as a vector. We conjugated
the peptide on the surface of both IONP and Cu4-NP, which
are similar in terms of chemical composition and thickness of
the organic layer. Using EDC/sulfoNHS to activate carboxylic
groups on the surface, we bound the RGD peptide by amide
formation with citric acid carboxylate groups. We measured the
hydrodynamic size and ζ-potential for the RGD-functionalized
nanoparticles (Figure S6), showing a different value of 31.9 nm
for Cu4-NP−RGD and 37.3 nm for IONP−RGD. ζ-Potential
values are the same in both cases, suggesting a similar
functionalization of the surface (−12.9 mV for Cu4-NP−RGD
vs −12.0 mV for IONP−RGD). After RGD quantification on
the nanoparticle surface (Bradford assay), we obtained a value
of 16.1 RGD molecules per IONP and 15.9 molecules of RGD
per Cu4-NP. We performed in vivo MRI experiments in mouse
breast cancer allograft models, after the intravenous injection
of four different nanoparticles, IONP, Cu4-NP, IONP−RGD,
and Cu4-NP−RGD.
Figure 6 shows the MR data obtained 1 h after the
intravenous injection of the different NPs. We show images
with the normal contrast (left panels in each image) and also
setting the muscle contrast intensity to 0 (right panels in each
image) to better appreciate the possible increase in the tumor
signal. Differences are dramatic. First, we can discard the
accumulation of the nanoparticles in the tumor due to the
enhanced permeability and retention effect since there is no
significant signal in the tumor after the injection of either
IONP (Figure 6a) or Cu4-NP (Figure 6c). The situation is
different after the injection of the functionalized NPs. The
image after the injection of IONP−RGD shows a modest
increase in the tumor signal (Figure S7); however, when
muscle pixels are set to 0, the tumor is barely distinguishable
from this reference. The situation is completely different for
Cu4-NP−RGD. Figure 6d (left panel) clearly shows an
increase in the signal compared to that from the muscle and
also when compared to that in Figure 6c. This signal increase is
even more clearly displayed when the muscle intensity is set to
0; the tumor is clearly observable owing to a 30% increase in
the MRI signal (Figure S6). The difference in hydrodynamic
size between IONP−RGD and Cu4-NP−RGD (Figure S6)
can contribute to this difference but in a minor proportion.
The main reason for this outstanding result obtained with
Cu4-NP−RGD is the very large r1 value obtained, significantly
larger than the r1 value for the undoped nanoparticles. To
further explain this, we measured the relaxivity values for Cu4-
NP and IONP at 7 T. We measured r1 values of 2.7 mM
−1 s−1
for Cu4-NP and 2.8 mM−1 s−1 for IONP. However, the r2
values are 38.7 mM−1 s−1 for Cu4-NP and 88.5 mM−1 s−1 for
IONP. These values permit us to get a good T1 contrast at a
high field with Cu4-NP samples but not with IONP because of
the large r2 value, explaining the large differences observed at 7
T in vivo for tumor detection.
3. CONCLUSIONS
The search for better contrast agents for magnetic resonance
imaging has implications for both basic and translational
research. The synthesis and application of nanoparticles for
positive contrast are particularly interesting since these will
boost the use of nanomaterials in this imaging technique, key
for many clinical applications. In this work, we show for the
first time how the use of Cu, as a dopant, enhances the positive
contrast in vivo performance of iron oxide nanoparticles. We
have fully characterized the nanoparticles and demonstrated
the in vivo use of this nanomaterial, both as a blood pool
contrast agent and for targeted molecular imaging, which is key
for further development and applications. The relaxometric
values, the type of synthesis, and the in vivo performance make
Cu4-NP a remarkable candidate for future clinical translation.
4. EXPERIMENTAL SECTION
4.1. Synthesis of IONP−Citrate Samples. A mixture of
FeCl3·6H2O (75 mg) and citric acid trisodium salt (80 mg)
was dissolved in water (9 mL). Subsequently, hydrazine
Figure 6. Magnetic resonance imaging of breast tumor-bearing mice allografts 1 h after the intravenous injection of 0.05 mmol Fe kg−1 of (a)
IONP, (b) IONP−RGD, (c) Cu4-NP, and (d) Cu4-NP−RGD. Left panels show normal contrast images, and right panels are obtained after setting
the muscle intensity to 0 to highlight the possible increase in the tumor signal. All MRI images were acquired (see the Experimental Section) with
the same parameters.
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monohydrate (1 mL) was added and the mixture was rapidly
introduced into the microwave. Samples were heated under
vigorous stirring at 240 W for 10 min at 120 °C. Once this step
was completed, nanoparticles were purified through a gel
filtration column (PD10) to eliminate unreacted species and
stored in glass vials for further characterization.
4.2. Synthesis of Cu-NP−Citrate Samples. A mixture of
FeCl3·6H2O (75 mg), citric acid trisodium salt (80 mg), and
CuCl2 (2, 6, or 10 mg) was dissolved in water (9 mL).
Subsequently, hydrazine monohydrate (1 mL) was added and
the mixture was rapidly introduced into the microwave.
Samples were heated under vigorous stirring at 240 W for 10
min at 120 °C. Once this step was completed, nanoparticles
were purified through a gel filtration column (PD10) to
eliminate unreacted species and stored in glass vials for further
characterization.
4.3. Cu-NP Treatment with Citrate Lyase. Citrate lyase
(300 μL, 40 mg mL−1 in PBS 1×) was added to 1 mL of each
Cu-NP sample. The mixture was kept under vigorous stirring
for 90 min at room temperature. Once this step was
completed, samples were purified by ultrafiltration using 10
kDa cutoff filters and resuspended in water.
4.4. Synthesis of IONP−RGD. The cycloRGD peptide
was covalently attached to carboxyl groups in the citrate
coating by EDC/sulfoNHS chemistry, yielding IONP−RGD.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochlor-
ide (EDC, 12 mg) and 15 mg of N-hydroxysulfosuccinimide
(NHS) were added to 5 mL of IONP. The mixture was stirred
at room temperature for 30 min and posteriorly purified by
ultrafiltration using 30 kDa cutoff filters. Filtered nanoparticles
were diluted in buffer 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES) pH 8 to 1.8 mL and 1 mg of cycloRGD
was then added and mixture stirred at room temperature for 60
min. Once this step was completed, the sample was purified by
ultrafiltration and resuspended in saline.
4.5. Synthesis of Cu-NP−RGD. CycloRGD was covalently
attached to carboxyl groups in the citrate coating by EDC/
sulfoNHS chemistry, yielding Cu-NP−RGD. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, 12
mg) and 15 mg of N-hydroxysulfosuccinimide (NHS) were
added to 5 mL of Cu-NP. The mixture was stirred at room
temperature for 30 min and posteriorly purified by ultra-
filtration using 30 kDa cutoff filters. Filtered nanoparticles were
diluted in buffer HEPES, pH 8, to 1.8 mL and 1 mg of
cycloRGD was then added, and the mixture stirred at room
temperature for 60 min. Once this step was completed, the
sample was purified by ultrafiltration and resuspended in saline.
4.6. IONP and Cu-NP Hydrodynamic Size and ζ-
Potential Measurements. Hydrodynamic size and ζ-
potential of samples were measured using dynamic light
scattering (DLS). A Zetasizer Nano ZS (Malvern Instruments)
was used to this end. This device is equipped with a He−Ne
laser operating at 633 nm and 4 mW and an avalanche
photodiode detector.
4.7. MRI Relaxation Properties of IONP and Cu-NP.
Relaxometric properties of the samples were assessed by
measuring longitudinal and transverse relaxation times. Four
concentrations of each nanoparticle sample were selected, and
longitudinal and transversal relaxation times of each one were
measured using a Bruker Minispec mq60 contrast agent
analyzer at 1.5 T and 37 °C. The r1 and r2 values were plotted
against the Fe concentration (0, 0.25, 0.5, 1, and 2 mM).
4.8. In Vivo MRI Acquisition.MRI equipment used in this
study was an Agilent/Varian scanner (Agilent, Santa Clara,
CA) equipped with a DD2 console and an actively shielded
205/120 gradient insert coil with 130 mT m−1 maximum
gradient strength, a TX/RX volume quadrature coil, and a 1H
circularly polarized transmit−receive volume coil of 35 mm
inner diameter and 30 mm active length built by Neos Biotec
(Pamplona, Spain). For angiography study, mice weighing 30 g
were anesthetized with 2% isoflurane and oxygen before being
placed on a thermoregulated (38 °C) mouse bed. An
ophthalmic gel was applied in the eyes to prevent retinal
damage due to drying. The three-dimensional gradient echo
with magnetization transfer contrast (MTC) prepulse MRA
was performed with the following parameters: min TR, 12.64
ms; min TE, 2.32 ms; flip angle, 20°; two averages; acquisition
matrix, 256 × 192 × 128; MTC flip angle, 810°; duration, 6
ms; and offset frequency, 2000 Hz. For tumor MRI
experiments, axial T1-weighted spin echo images were acquired
with the following parameters: TR, 2072 ms; TE, 27.9 ms; NA,
8; matrix, 256 × 256; FOV, 30 × 30 mm2; 20 consecutive 0.5
mm slices; and spectral width, 125 000 Hz.
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